INTRODUCTION {#s1}
============

The mouse mammary tumor virus (MMTV) is a saliva- and milk-transmitted retrovirus \[[@R1]-[@R5]\]; however, infected mice only develop mammary tumors in adulthood \[[@R4]\]. This long latency period makes MMTV an interesting virus for understanding the pathogenesis of human breast cancers \[[@R6]\]. The provirus inserts upstream of two key integration sites, named Int-1 and Int-2 \[[@R7]-[@R10]\]. This process of insertional mutatgenesis is thought to be random, but involves the positive selection of genes that will ultimately provide an increase in "stemness", a cellular growth-advantage, or perhaps both. MMTV tumors are oligo-clonal, suggesting that there is some synergy between these two different integration sites. These mammary proto-oncogenes Int-1 and Int-2 have been identified as WNT1 and FGF3 \[[@R11]-[@R13]\], two secreted growth factors normally involved in stem cell signaling pathways.

WNT1 is the first member of the WNT gene family, which is known to be involved in cell fate determination and patterning during embryogenesis \[[@R14], [@R15]\]. FGF3 is a member of the fibroblast growth factor family, which controls cell proliferation, morphogenesis and tissue repair \[[@R16]\]. Interestingly, WNT1 and FGF3 converge directly upon the WNT/β-catenin signaling cascade \[[@R17], [@R18]\]. However, it remains largely unknown exactly how WNT1/FGF3 signaling induces mammary tumorigenesis.

Here, we have created a humanized model of MMTV signaling, by over-expressing WNT1 and FGF3 in human breast cancer cells, namely MCF7 cells, an ER(+) cell line. Unbiased label-free proteomic analysis of this model system reveals the induction of EMT markers, mitochondrial proteins, glycolytic enzymes and protein synthesis machinery, consistent with an anabolic CSC phenotype. The proteins that were up-regulated by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in human breast cancer cells *in vivo*. This isogenic cell model should accelerate the identification and development of new protein biomarkers to predict clinical outcomes in breast cancer patients.

Finally, we also show that mitochondrial mass is a new metabolic biomarker for anabolic CSCs, as assessed by MitoTracker vital-staining and metabolic cell fractionation by flow-cytometry.

RESULTS {#s2}
=======

Generating a humanized model of MMTV signaling {#s2_1}
----------------------------------------------

During MMTV infection of mammary epithelial cells, genomic viral integration occurs. This ultimately leads to mammary tumorigenesis in mice. Mechanistically, the MMTV virus uses a promoter insertion mechanism of mutagenesis, to drive oncogenesis \[[@R19]\]. More specifically, the MMTV promoter inserts upstream of two main integration sites, namely Int-1 (Wnt1) or Int-2 (Fgf3), although a few other rare integration sites have been described \[[@R11]-[@R13], [@R20]\] (Table [1](#T1){ref-type="table"}). As a consequence, the MMTV promoter drives the over-expression of these secreted stem cell associated growth factors, constitutively activating Wnt/β-catenin signaling \[[@R11], [@R21], [@R22]\]. Thus, the MMTV model has been instrumental for understanding how "amplified" or "constitutive" stem cell signaling directly contributes to solid tumor formation (Figure [1](#F1){ref-type="fig"}). As such, it would be beneficial to create a humanized non-infectious model of MMTV signaling, to drive the discovery of new stem cell associated biomarkers, for predicting clinical outcome in human breast cancer patients.

![Creating a humanized experimental model for MMTV: Focus on WNT1 and FGF3 signaling\
To create a humanized model of MMTV signaling, we recombinantly over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. WNT1 and FGF3 were expressed either individually or in combination, using lenti-viral vectors carrying two different selection markers (puromycin or neomycin/G418). This isogenic cell model of "stemness" was generated to facilitate protein biomarker discovery in breast cancer, via unbiased label-free proteomics. Importantly, over-expression of FGF3, WNT1, or WNT1/FGF3 increases mammosphere formation by 1.5-, 2.5- and 3.5-fold, respectively (See Figure [2](#F2){ref-type="fig"}). Thus, we focused on MCF7-WNT1/FGF3 cells for further validation and proteomic analysis.](oncotarget-06-30453-g001){#F1}

###### MMTV common proviral integration sites and gene designations

  Integration site(s)   Gene Name
  --------------------- --------------------------------------------------
  Int-1                 Wnt-1
  Int-2                 Fgf-3
  Int-3                 Notch-4
  Int-4                 Wnt-3
  Int-5                 Aromatase; Cyp19a1
  Int-6                 Eukaryotic translation initiation factor 3; eIF3
  Int-7                 Rspo-2

Additional genes include Fgf-4, Wnt-3a and Wnt-10, among others.

Thus, in order to create a humanized model of MMTV signaling, we recombinantly over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. WNT1 and FGF3 were expressed either individually or in combination, using lentiviral vectors carrying two different selection markers (puromycin or neomycin/G418). For comparison purposes, empty vector controls (EV) were generated in parallel (Figure [1](#F1){ref-type="fig"}).

Then, the various cell lines were screened for stem cell activity, using the mammosphere assay as a functional readout. Importantly, Figure [2A](#F2){ref-type="fig"} directly validates that over-expression of either WNT1 or FGF3 is sufficient to increase the clonal expansion of cancer stem cells. Interestingly, FGF3 and WNT1 significantly increased mammosphere formation by ∼1.5-fold and ∼2.5-fold, respectively. However, MCF7 cells over-expressing both WNT1 and FGF3 showed the largest increase in mammosphere formation, by up to ∼3.5-fold (Figure [2A](#F2){ref-type="fig"}).

###### Recombinant over-expression of WNT1 and/or FGF3 in MCF7 cells significantly augments mammosphere formation

**A) Mammosphere formation**. The cell lines we generated were screened for stem cell activity, using the mammosphere assay as a functional readout. Note that over-expression of either WNT1 or FGF3 significantly increased mammosphere formation by ∼1.5-fold and ∼2.5-fold, respectively. However, MCF7 cells over-expressing both WNT1 and FGF3 showed the largest increase in mammosphere formation, by up to ∼3.5-fold. Results were normalized to the three control cell lines harboring either i) EX-Neg-Lv105(puro), ii) EX-Neg-Lv151(neo) or iii) both control vectors. P-values are as indicated. Assays were performed in triplicate and repeated three times independently. MFE, mammosphere forming efficiency. **B) Immunoblot analysis**. Recombinant over-expression of WNT1 and FGF3 in these transfected cell models was validated by immunoblot analysis, with specific antibody probes. Beta-actin is shown as a control for equal loading.

![](oncotarget-06-30453-g002a)

![](oncotarget-06-30453-g002b)

We also validated the recombinant over-expression of WNT1 and FGF3 in these transfected cell models by immunoblot analysis, with specific antibody probes (Figure [2B](#F2){ref-type="fig"}).

Conditioned media from MCF7-WNT1/FGF3 cells is sufficient to increase mammosphere formation {#s2_2}
-------------------------------------------------------------------------------------------

As WNT1 and FGF3 are secreted factors, it would be predicted that the increase in constitutive stem cell signaling could also act in a paracrine fashion on non-transfected cells. To test this hypothesis, we prepared conditioned media from MCF7-WNT1/FGF3 cells and the corresponding empty vector (MCF7-EV) control cells.

Then, we compared the ability of conditioned media to support mammosphere formation, in untransfected parental MCF7 cells. Figure [3](#F3){ref-type="fig"} (Left) shows that conditioned media prepared from MCF7-WNT1/FGF3 cells significantly stimulated mammosphere formation by ∼2-fold. Importantly, virtually identical results were obtained with untransfected parental T47D cells, a second independent ER(+) breast cancer cell line (Figure [3](#F3){ref-type="fig"} (Right)).

![Conditioned media from WNT1/FGF3 expressing MCF7 cells increases mammosphere formation\
Since WNT1 and FGF3 are secreted factors, they should act in a paracrine fashion on non-transfected cells. To test this hypothesis, we prepared conditioned media from MCF7-WNT1/FGF3 cells and the corresponding empty vector (MCF7-EV) control cells. Then, we compared the ability of this conditioned media to support mammosphere formation, in untransfected parental MCF7 cells (Left panel). Note that conditioned media prepared from MCF7-WNT1/FGF3 cells significantly stimulated mammosphere formation by ∼2-fold. Nearly identical results were obtained with untransfected parental T47D cells, a second independent ER(+) breast cancer line (Right panel). Assays were performed in triplicate and repeated three times independently. MFE, mammosphere forming efficiency.](oncotarget-06-30453-g003){#F3}

Proteomics analysis of MCF7-WNT1/FGF3 cells reveals the upregulation of EMT markers, mitochondrial proteins, glycolytic enzymes, and the protein synthesis machinery {#s2_3}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

To better understand how WNT and FGF signaling drive the expansion of CSCs, we used unbiased label-free proteomics analysis. The proteome of MCF7-WNT1/FGF3 cells was compared to MCF7-EV control cells. We restricted our analysis to protein products that were over-expressed by \>1.5-fold. Overall, our results are detailed in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### Key Molecules Up-regulated by WNT1/FGF3 in MCF7 Cells: Mitochondria and Glycolysis

  Symbol                                                                                                                        Description                                                                     Fold-Change   ANOVA
  ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------- ----------
  **Mitochondrial-related Proteins/TCA Cycle (42)**                                                                                                                                                                           
  ACO2                                                                                                                          Aconitase 2, mitochondrial                                                      Infinity      1.61E-08
  IDH1                                                                                                                          Isocitrate dehydrogenase \[NADP\] 1                                             Infinity      0.004
  MDH1                                                                                                                          Malate dehydrogenase, cytoplasmic                                               28.32         2.11E-05
  CKMT2                                                                                                                         Creatine kinase S-type, mitochondrial                                           11.04         0.015
  FASN                                                                                                                          Fatty acid synthase                                                             7.77          0.036
  CKMT1                                                                                                                         Creatine kinase U-type, mitochondrial                                           7.60          2.12E-05
  CKMT1B                                                                                                                        Creatine kinase U-type, mitochondrial                                           6.27          5.74E-05
  CKMT1A                                                                                                                        Creatine kinase U-type, mitochondrial                                           5.19          7.98E-05
  OAT                                                                                                                           Ornithine aminotransferase, mitochondrial                                       4.79          0.0003
  PC                                                                                                                            Pyruvate carboxylase, mitochondrial                                             4.63          0.0001
  DUT                                                                                                                           Deoxyuridine 5′-triphosphate nucleotidohydrolase, mitochondrial                 3.85          0.0001
  TOMM34                                                                                                                        Translocase of outer mitochondrial membrane 34                                  2.89          0.0027
  GLUD2                                                                                                                         Glutamate dehydrogenase 2, mitochondrial                                        2.78          0.035
  MT-CO2                                                                                                                        Cytochrome c oxidase subunit 2 (COX2)                                           2.66          0.0017
  NQO1                                                                                                                          NAD(P)H dehydrogenase \[quinone\] 1                                             2.60          8.31E-05
  ACADVL                                                                                                                        Very long-chain-specific acyl-CoA dehydrogenase, mitochondrial                  2.46          0.0007
  C21orf33                                                                                                                      ES1 protein homolog, mitochondrial                                              2.37          0.01
  NDUFS1                                                                                                                        Mitochondrial NADH-ubiquinone oxidoreductase 75 kDa subunit                     2.27          0.0026
  SCD                                                                                                                           Acyl-CoA desaturase                                                             2.25          3.93E-05
  GPD2                                                                                                                          Glycerol-3-phosphate dehydrogenase, mitochondrial                               2.08          0.03
  HSPA9                                                                                                                         Stress-70 protein, mitochondrial                                                2.07          0.0498
  IDH3A                                                                                                                         Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial                   1.96          0.001
  HSPD1                                                                                                                         60 kDa heat shock protein, mitochondrial                                        1.95          0.02
  ETFA                                                                                                                          Electron transfer flavoprotein subunit alpha, mitochondrial                     1.91          0.03
  ABAT                                                                                                                          4-aminobutyrate aminotransferase, mitochondrial                                 1.85          0.03
  PRDX5                                                                                                                         Peroxiredoxin-5, mitochondrial                                                  1.83          0.037
  COX4I1                                                                                                                        Cytochrome c oxidase subunit 4 isoform 1, mitochondrial                         1.83          0.007
  COX6A1                                                                                                                        Cytochrome c oxidase subunit 6A, mitochondrial                                  1.81          0.002
  TUFM                                                                                                                          Elongation factor Tu, mitochondrial                                             1.78          0.02
  ATP5O                                                                                                                         ATP synthase subunit O, mitochondrial                                           1.77          0.004
  CLPX                                                                                                                          ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial         1.72          0.016
  CS                                                                                                                            Citrate synthase, mitochondrial                                                 1.71          0.001
  ECHS1                                                                                                                         Enoyl-CoA hydratase, mitochondrial                                              1.70          0.004
  ATP5B                                                                                                                         ATP synthase subunit beta, mitochondrial                                        1.69          0.039
  PCK2                                                                                                                          Phosphoenolpyruvate carboxykinase \[GTP\], mitochondrial                        1.66          0.001
  AK2                                                                                                                           Adenylate kinase 2, mitochondrial                                               1.65          0.004
  ATP5A1                                                                                                                        ATP synthase subunit alpha, mitochondrial                                       1.61          0.02
  ETFB                                                                                                                          Electron-transfer-flavoprotein, beta                                            1.60          0.02
  PRKDC                                                                                                                         DNA-dependent protein kinase catalytic subunit (maintains mt-DNA copy number)   1.58          0.03
  CHCHD2P9                                                                                                                      Coiled-coil-helix-coiled-coil-helix domain-protein CHCHD2P9, mitochondrial      1.57          0.02
  AIFM1                                                                                                                         Apoptosis-inducing factor 1, mitochondrial                                      1.53          0.006
  UQCRFS1P1                                                                                                                     Putative cytochrome b-c1 complex subunit Rieske-like protein 1                  1.50          0.02
  **Enzymes Related to Glycolysis, the Pentose Phosphate Pathway, Glycogen, and Amino Acid Synthesis (Serine/Arginine) (14)**                                                                                                 
  PHGDH                                                                                                                         D-3-phosphoglycerate dehydrogenase                                              Infinity      2.68E-13
  ASS1                                                                                                                          Argininosuccinate synthase                                                      17.39         3.42E-09
  HK2                                                                                                                           Hexokinase-2                                                                    11.57         3.15E-08
  PKM2                                                                                                                          Pyruvate kinase                                                                 2.83          0.003
  PYGB                                                                                                                          Glycogen phosphorylase, brain form                                              2.23          0.01
  PFKL                                                                                                                          6-phosphofructokinase, liver type                                               2.17          0.004
  CAD                                                                                                                           Glutamine-dependent carbamoyl-phosphate synthase                                2.08          0.0007
  PKLR                                                                                                                          Pyruvate kinase isozymes R/L                                                    2.08          1.46E-05
  PGAM4                                                                                                                         Probable phosphoglycerate mutase 4                                              1.94          0.005
  G6PD                                                                                                                          Glucose-6-phosphate 1-dehydrogenase                                             1.89          0.005
  TKT                                                                                                                           Transketolase                                                                   1.64          0.003
  PGK2                                                                                                                          Phosphoglycerate kinase 2                                                       1.57          0.006
  ENO1                                                                                                                          Enolase, alpha                                                                  1.51          0.007
  PGK1                                                                                                                          Phosphoglycerate kinase                                                         1.50          0.04

###### Key Molecules Up-regulated by WNT1/FGF3 in MCF7 Cells: The EMT and Cell Migration

  Symbol                                                                                 Description                                                                    Fold-Change   ANOVA
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------- --------------
  **EMT Markers, Extracellular Matrix, Cell Migration and Cytoskeletal proteins (47)**                                                                                                
  MARCKS                                                                                 Myristoylated alanine-rich C-kinase substrate                                  371.76        3.72E-05
  S100A14                                                                                Protein S100-A14                                                               96.23         0.0002
  CDC42                                                                                  Cell division control protein 42 homolog                                       68.67         5.27E-06
  LGALS3BP                                                                               Galectin-3-binding protein                                                     38.46         0.001
  **FRS2**                                                                               **Fibroblast growth factor receptor substrate 2**                              **11.59**     **9.69E-05**
  MAST4                                                                                  Microtubule-associated serine/threonine-protein kinase 4                       10.81         2.62E-05
  CALML5                                                                                 Calmodulin-like protein 5                                                      8.06          0.0007
  CDV3                                                                                   Carnitine deficiency-associated gene expressed in cardiac ventricle 3          7.67          7.58E-06
  SCUBE1                                                                                 Signal peptide, CUB domain, EGF-like 1                                         6.84          1.97E-05
  S100A11                                                                                Protein S100-A11                                                               6.66          0.026
  S100A16                                                                                Protein S100-A16                                                               6.41          0.0003
  MERTK                                                                                  Tyrosine-protein kinase MER                                                    6.24          4.40E-05
  NINJ1                                                                                  Ninjurin-1                                                                     5.36          0.0001
  TTBK2                                                                                  Tau-tubulin kinase                                                             5.31          4.15E-05
  EMD                                                                                    Emerin                                                                         4.38          0.0006
  FLNB                                                                                   Filamin-B                                                                      4.27          0.004
  TTN                                                                                    Titin                                                                          3.66          7.32E-05
  CGNL1                                                                                  Cingulin-like protein 1                                                        3.62          0.005
  TAGLN2                                                                                 Transgelin-2                                                                   2.94          0.02
  ACTA2                                                                                  Actin, aortic smooth muscle                                                    2.86          0.0002
  TLN1                                                                                   Talin-1                                                                        2.78          0.008
  SEPT2                                                                                  Septin-2                                                                       2.77          0.004
  HMGB1                                                                                  High mobility group protein B1                                                 2.66          0.001
  TPT1                                                                                   Translationally-controlled tumor protein                                       2.54          0.028
  AMOT                                                                                   Angiomotin                                                                     2.40          0.008
  **CTNNB1**                                                                             **Catenin, beta-1**                                                            **2.37**      **0.0003**
  TRIOBP                                                                                 TRIO and F-actin-binding protein                                               2.35          0.003
  ASAP2                                                                                  Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2         2.23          0.01
  MYH14                                                                                  Myosin-14                                                                      2.20          0.02
  S100A10                                                                                S100A10 protein                                                                2.13          0.0002
  TAX1BP3                                                                                Tax1-binding protein 3                                                         2.13          0.0002
  HMGB3                                                                                  High mobility group protein B3                                                 2.10          0.01
  FLNA                                                                                   Filamin-A                                                                      2.08          0.004
  MYO18B                                                                                 Myosin XVIIIB                                                                  1.99          0.0005
  IQGAP1                                                                                 IQ motif containing GTPase activating protein 1 (scaffold protein for CDC42)   1.98          0.026
  ACTN2                                                                                  Alpha-actinin-2                                                                1.96          1.64E-05
  ANXA2                                                                                  Annexin A2                                                                     1.90          0.01
  TAGLN3                                                                                 Transgelin-3                                                                   1.89          0.01
  FAM129B                                                                                Niban-like protein 1 (associated with cell invasion)                           1.88          0.0008
  ACTN3                                                                                  Alpha-actinin-3                                                                1.81          0.025
  FAM82B                                                                                 Regulator of microtubule dynamics protein 1                                    1.80          0.02
  MYH10                                                                                  Myosin, heavy polypeptide 10, non-muscle                                       1.79          0.04
  MYOF                                                                                   Myoferlin                                                                      1.60          0.0026
  CAPZB                                                                                  F-actin-capping protein subunit beta                                           1.58          0.04
  MTPN                                                                                   Myotrophin                                                                     1.57          0.007
  TUBB2A                                                                                 Tubulin beta-2A chain                                                          1.56          0.0045
  EPPK1                                                                                  Epiplakin                                                                      1.51          0.0485
  **Miscellaneous (17)**                                                                                                                                                              
  CAST                                                                                   Calpastatin A                                                                  21.60         0.005
  SH3BGRL                                                                                SH3 domain-binding glutamic acid-rich-like protein                             14.23         0.0003
  SEC24A                                                                                 Protein transport protein Sec24A                                               12.52         7.39E-05
  PABPC4                                                                                 Polyadenylate-binding protein 4                                                6.53          0.0006
  C10orf12                                                                               Uncharacterized protein C10orf12                                               5.71          3.46E-05
  TMED4                                                                                  Transmembrane emp24 domain-containing protein 4                                4.99          4.34E-05
  PTMS                                                                                   Parathymosin                                                                   4.66          0.0001
  HUWE1                                                                                  E3 ubiquitin-protein ligase HUWE1                                              4.50          5.23E-05
  PON2                                                                                   Paraoxonase 2, isoform                                                         4.28          0.003
  AHNAK                                                                                  Neuroblast differentiation-associated protein, AHNAK                           3.68          0.0002
  COMT                                                                                   Soluble catechol-O-methyltransferase                                           3.66          0.002
  STUB1                                                                                  E3 ubiquitin-protein ligase CHIP                                               3.38          0.0001
  TMEM205                                                                                Transmembrane protein 205 (chemo-resistance to cisplatin)                      2.92          1.55E-05
  TFF1                                                                                   Trefoil factor 1                                                               2.30          0.005
  MATR3                                                                                  Matrin-3                                                                       2.25          0.038
  SRRM2                                                                                  Serine/arginine repetitive matrix protein 2                                    2.19          0.03
  ARF5                                                                                   ADP-ribosylation factor 5                                                      2.06          0.009

Genes encoding **FRS2** and **CTNNB1** are highlighted in **BOLD,** as they would be expected to amplify FGF and WNT signaling, respectively.

###### Key Molecules Up-regulated by WNT1/FGF3 in MCF7 Cells: Ribosomes and Protein Synthesis

  Symbol                                                      Description                                                                      Fold-Change   ANOVA
  ----------------------------------------------------------- -------------------------------------------------------------------------------- ------------- ----------
  **Ribosome-related proteins (8)**                                                                                                                          
  RPL13                                                       60S ribosomal protein L13                                                        6.65          7.43E-07
  NPM1                                                        NPM1 protein                                                                     3.78          0.001
  RPL14                                                       60S ribosomal protein L14                                                        3.41          0.001
  SRPRB                                                       Signal recognition particle receptor subunit beta                                2.11          0.002
  RPL4                                                        60S ribosomal protein L4                                                         2.04          0.01
  RPS5                                                        40S ribosomal protein S5                                                         1.99          0.006
  RPL15                                                       60S ribosomal protein L15                                                        1.99          0.004
  RPL13                                                       60S ribosomal protein L19                                                        1.50          0.01
  **Translation initiation factors (5)**                                                                                                                     
  EIF5A                                                       Eukaryotic translation initiation factor 5A                                      7.22          0.03
  EIF5B                                                       Eukaryotic translation initiation factor 5B                                      2.25          3.38E-06
  EIF6                                                        Eukaryotic translation initiation factor 6                                       2.24          0.028
  EIF2S1                                                      Eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa               1.55          0.0035
  EIF3D                                                       Eukaryotic translation initiation factor 3 subunit D                             1.51          0.03
  **Elongation factors (4)**                                                                                                                                 
  EEF1B2                                                      Elongation factor 1-beta                                                         1.95          0.0498
  TUFM                                                        Elongation factor Tu, mitochondrial                                              1.78          0.02
  EEF1D                                                       Elongation factor 1-delta                                                        1.70          0.03
  EEF1G                                                       Elongation factor 1-gamma                                                        1.52          0.001
  **Enzymes for tRNA synthesis (6)**                                                                                                                         
  DARS                                                        Aspartate\--tRNA ligase, cytoplasmic                                             3.23          0.0001
  WARS                                                        Tryptophan\--tRNA ligase, cytoplasmic                                            2.54          0.0016
  LARS                                                        Leucine\--tRNA ligase, cytoplasmic                                               1.90          0.002
  FARSB                                                       Phenylalanine\--tRNA ligase beta subunit                                         1.69          0.005
  EPRS                                                        Bifunctional aminoacyl-tRNA synthetase (Glutamyl-Prolyl-tRNA Synthetase)         1.65          0.006
  C22orf28                                                    tRNA-splicing ligase RtcB homolog                                                1.56          0.008
  **Protein folding chaperones (heat shock proteins) (14)**                                                                                                  
  PDIA3                                                       Protein disulfide-isomerase A3                                                   3.59          2.39E-05
  PPIB                                                        Peptidyl-prolyl cis-trans isomerase B                                            3.39          1.90E-06
  CALU                                                        Calumenin                                                                        2.93          0.0002
  PDIA6                                                       Protein disulfide-isomerase A6                                                   2.82          0.001
  PDIA4                                                       Protein disulfide-isomerase A4                                                   2.68          0.004
  HSPA1B                                                      Heat shock 70 kDa protein 1                                                      2.43          0.0003
  HSPD1                                                       60 kDa heat shock protein, mitochondrial                                         1.95          0.02
  HSP90AB3P                                                   Putative heat shock protein HSP 90-beta-3                                        1.61          0.026
  HSPA8                                                       Heat shock cognate 71 kDa protein                                                1.60          0.02
  HSP90B1                                                     Endoplasmin                                                                      1.60          0.006
  HSPH1                                                       Heat shock protein 105 kDa                                                       1.60          0.047
  PPIA                                                        Peptidyl-prolyl cis-trans isomerase A                                            1.60          0.02
  HSP90AB1                                                    Heat shock protein HSP 90-beta                                                   1.57          0.049
  CANX                                                        Calnexin                                                                         1.54          0.01
  **Amino acid transport (2)**                                                                                                                               
  SLC1A5                                                      Neutral amino acid transporter B(0)                                              2.77          0.0004
  SLC7A5                                                      Solute carrier family 7 (Cationic amino acid transporter, y+ system), member 5   1.66          0.04

Remarkably, \>40 nuclear-encoded mitochondrial-related proteins were over-expressed in MCF7-WNT1/FGF3 cells (Table [2](#T2){ref-type="table"}). Many of these proteins were related to the TCA cycle (ACO2), oxidative phosphorylation (MT-CO2), regenerating ATP (CKMT1/2) or mitochondrial biogenesis (TOMM34). In addition, MT-CO2 (a mitochondria-DNA encoded protein) was upregulated by \>2.5-fold, indicative of the production of new mitochondria. In support of an anabolic phenotype, proteins related to glycolysis, the pentose phosphate pathway, glycogen metabolism and amino acid synthesis were upregulated (Table [2](#T2){ref-type="table"}).

Stem-like cancer cells also undergo an epithelial-mesenchymal transition (EMT), which promotes cell migration, invasion and distant metastasis \[[@R23]\]. Importantly, \>45 proteins known to be associated with the EMT phenotype (cell migration or invasiveness) were upregulated in MCF7-WNT1/FGF3 cells (Table [3](#T3){ref-type="table"}). Examples include FRS2 (FGF receptor substrate-2; \>10-fold) and β-catenin (\>2-fold), which would be expected to further amplify WNT/FGF signaling, as these are down-stream elements of these convergent signaling networks. Similarly, other signaling molecules that promote the EMT and cell migration were significantly upregulated, such as MARCKS (\>370-fold) and CDC42 (\>65-fold).

Finally, augmented protein synthesis is another characteristic of anabolic CSCs. Note that MCF7-WNT1/FGF3 cells show the upregulation of \>35 proteins related to protein synthesis (Table [4](#T4){ref-type="table"}). Examples include ribosome-related proteins (RPS and RPL), translation initiation factors (EIFs), peptide elongation factors (EEFs), enzymes for tRNA synthesis, as well as chaperones for protein folding (HSPs) and amino acid transporters (SLC).

Thus, MCF7-WNT1/FGF3 cells upregulate greater than 140 proteins that would be consistent with an overall anabolic phenotype (Figure [4](#F4){ref-type="fig"}).

![The anabolic CSC phenotype: Proteomics analysis\
Unbiased label-free proteomics analysis of MCF7-WNT1/FGF3 cells revealed the induction of i) mitochondrial proteins, ii) glycolytic enzymes, iii) protein synthesis machinery and iv) EMT markers, consistent with an anabolic CSC phenotype. For specific details, see Tables 2, 3 and 4. *Mitochondrial proteins --* Greater than 40 nuclear-encoded mitochondrial-related proteins were over-expressed in MCF7-WNT1/FGF3 cells. Many of these proteins were related to the TCA cycle (ACO2), oxidative phosphorylation (MT-CO2), regenerating ATP (CKMT1/2) or mitochondrial biogenesis (TOMM34). In addition, MT-CO2 (a mitochondrial DNA encoded protein) was upregulated by \>2.5-fold. *Glycolytic enzymes --* More than 10 enzymes related to glycolysis, the pentose phosphate pathway, glycogen metabolism and amino acid synthesis were all upregulated in MCF7-WNT1/FGF3 cells. *Protein synthesis machinery --* Over 35 proteins related to protein synthesis, including ribosome-related proteins, enzymes for tRNA synthesis, chaperones for protein folding and amino acid transporters, were all up upregulated in MCF7-WNT1/FGF3 cells. *EMT markers --* Greater than 45 proteins known to be associated with the EMT phenotype were upregulated in MCF7-WNT1/FGF3 cells. Examples include FRS2 (FGF receptor substrate-2; \>10-fold) and β-catenin (\>2-fold).](oncotarget-06-30453-g004){#F4}

Expression of WNT1/FGF3-related targets in patient-derived human breast cancer samples {#s2_4}
--------------------------------------------------------------------------------------

To determine the possible translational significance of our results, we intersected our WNT-FGF proteomics data with human genome-wide transcriptional profiling data. These human clinical data were derived from publically available human breast cancer samples, in which breast cancer cells were separated by laser-capture microdissection from tumor stromal cells. Transcriptional profiles were analyzed from from N=28 human breast cancer patients (See the *Materials & Methods section*). In this data set, gene expression was previously determined using Affymetrix U133A 2.0 GeneChips. A concise summary of these findings is presented in Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}. Overall, greater than sixty WNT1/FGF3 targets (related to mitochondria, glycolysis, the EMT, and protein synthesis) that we identified in MCF7-WNT1/FGF3 cells were also transcriptionally elevated in human breast cancer cells *in vivo*. These new protein targets that we identified in MCF7-WNT1/FGF3 cells may be important for developing new strategies for the diagnosis and treatment of breast cancer.

###### WNT1/FGF3 Targets Increased in Human Breast Cancer Cells *in Vivo*: Mitochondria and Glycolysis

  Symbol                                                                                                                       Description                                                                     Fold-Change   P-value
  ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------- ----------
  **Mitochondrial-related Proteins/TCA Cycle (26)**                                                                                                                                                                          
  ATP5O                                                                                                                        ATP synthase subunit O, mitochondrial                                           5.12          2.13E-06
  ATP5B                                                                                                                        ATP synthase subunit beta, mitochondrial                                        5.04          2.75E-06
  ATP5A1                                                                                                                       ATP synthase subunit alpha, mitochondrial                                       5.01          3.09E-06
  COX6A1                                                                                                                       Cytochrome c oxidase subunit 6A, mitochondrial                                  4.46          2.07E-05
  ECHS1                                                                                                                        Enoyl-CoA hydratase, mitochondrial                                              4.05          8.22E-05
  MDH1                                                                                                                         Malate dehydrogenase, cytoplasmic                                               3.99          9.88E-05
  PCK2                                                                                                                         Phosphoenolpyruvate carboxykinase \[GTP\], mitochondrial                        3.88          1.43E-04
  SCD                                                                                                                          Acyl-CoA desaturase                                                             3.70          2.55E-04
  HSPA9                                                                                                                        Stress-70 protein, mitochondrial                                                3.69          2.64E-04
  NQO1                                                                                                                         NAD(P)H dehydrogenase \[quinone\] 1                                             3.49          4.81E-04
  HSPD1                                                                                                                        60 kDa heat shock protein, mitochondrial                                        3.42          5.93E-04
  COX4I1                                                                                                                       Cytochrome c oxidase subunit 4 isoform 1, mitochondrial                         3.39          6.61E-04
  TUFM                                                                                                                         Elongation factor Tu, mitochondrial                                             3.38          6.74E-04
  C21orf33                                                                                                                     ES1 protein homolog, mitochondrial                                              3.31          8.40E-04
  NDUFS1                                                                                                                       Mitochondrial NADH-ubiquinone oxidoreductase 75 kDa subunit                     3.20          1.15E-03
  IDH1                                                                                                                         Isocitrate dehydrogenase \[NADP\] 1                                             3.18          1.22E-03
  OAT                                                                                                                          Ornithine aminotransferase, mitochondrial                                       3.17          1.25E-03
  CS                                                                                                                           Citrate synthase, mitochondrial                                                 2.66          5.13E-03
  AK2                                                                                                                          Adenylate kinase 2, mitochondrial                                               2.20          1.59E-02
  IDH3A                                                                                                                        Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial                   2.16          1.78E-02
  PRKDC                                                                                                                        DNA-dependent protein kinase catalytic subunit (maintains mt-DNA copy number)   2.14          1.85E-02
  CLPX                                                                                                                         ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial         2.11          1.96E-02
  ABAT                                                                                                                         4-aminobutyrate aminotransferase, mitochondrial                                 2.08          2.14E-02
  ACO2                                                                                                                         Aconitase 2, mitochondrial                                                      1.83          3.64E-02
  DUT                                                                                                                          Deoxyuridine 5′-triphosphate nucleotidohydrolase, mitochondrial                 1.87          3.37E-02
  ETFA                                                                                                                         Electron transfer flavoprotein subunit alpha, mitochondrial                     1.76          4.25E-02
  **Enzymes Related to Glycolysis, the Pentose Phosphate Pathway, Glycogen, and Amino Acid Synthesis (Serine/Arginine) (4)**                                                                                                 
  PKM2                                                                                                                         Pyruvate kinase                                                                 3.26          9.79E-04
  PGK1                                                                                                                         Phosphoglycerate kinase                                                         2.46          8.66E-03
  TKT                                                                                                                          Transketolase                                                                   2.20          1.60E-02
  ENO1                                                                                                                         Enolase, alpha                                                                  1.96          2.75E-02

**-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and corresponding p-values derived from the analysis of these clinical samples.**

###### WNT1/FGF3 Targets Increased in Human Breast Cancer Cells *in Vivo*: The EMT and Cell Migration

  Symbol                                                                                 Description                                                                    Fold-Change   P-value
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------- ----------
  **EMT Markers, Extracellular Matrix, Cell Migration and Cytoskeletal proteins (15)**                                                                                                
  FLNB                                                                                   Filamin-B                                                                      4.81          6.21E-06
  TPT1                                                                                   Translationally-controlled tumor protein                                       3.43          5.81E-04
  CDC42                                                                                  Cell division control protein 42 homolog                                       3.11          1.48E-03
  S100A11                                                                                Protein S100-A11                                                               2.88          2.81E-03
  ANXA2                                                                                  Annexin A2                                                                     2.83          3.28E-03
  MYOF                                                                                   Myoferlin                                                                      2.67          5.00E-03
  TUBB2A                                                                                 Tubulin beta-2A chain                                                          2.63          5.56E-03
  SEPT2                                                                                  Septin-2                                                                       2.56          6.60E-03
  TAGLN2                                                                                 Transgelin-2                                                                   2.42          9.47E-03
  IQGAP1                                                                                 IQ motif containing GTPase activating protein 1 (scaffold protein for CDC42)   2.32          1.19E-02
  HMGB1                                                                                  High mobility group protein B1                                                 2.21          1.57E-02
  CAPZB                                                                                  F-actin-capping protein subunit beta                                           2.19          1.66E-02
  CDV3                                                                                   Carnitine deficiency-associated gene expressed in cardiac ventricle 3          2.04          2.30E-02
  FAM82B                                                                                 Regulator of microtubule dynamics protein 1                                    1.97          2.72E-02
  MYH10                                                                                  Myosin, heavy polypeptide 10, non-muscle                                       1.82          3.69E-02
  **Miscellaneous (11)**                                                                                                                                                              
  PON2                                                                                   Paraoxonase 2, isoform                                                         4.02          9.25E-05
  MATR3                                                                                  Matrin-3                                                                       3.45          5.56E-04
  SH3BGRL                                                                                SH3 domain-binding glutamic acid-rich-like protein                             3.12          1.43E-03
  AHNAK                                                                                  Neuroblast differentiation-associated protein, AHNAK                           2.57          6.41E-03
  CAST                                                                                   Calpastatin A                                                                  2.54          7.08E-03
  SEC24A                                                                                 Protein transport protein Sec24A                                               2.19          1.65E-02
  PABPC4                                                                                 Polyadenylate-binding protein 4                                                2.15          1.78E-02
  COMT                                                                                   Soluble catechol-O-methyltransferase                                           2.10          2.04E-02
  STUB1                                                                                  E3 ubiquitin-protein ligase CHIP                                               1.95          2.79E-02
  TFF1                                                                                   Trefoil factor 1                                                               1.76          4.17E-02
  HUWE1                                                                                  E3 ubiquitin-protein ligase HUWE1                                              1.75          4.33E-02

**-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and corresponding p-values derived from the analysis of these clinical samples.**

###### WNT1/FGF3 Targets Increased in Human Breast Cancer Cells *in Vivo*: Ribosomes and Protein Synthesis

  Symbol                                                      Description                                                                Fold-Change   P-value
  ----------------------------------------------------------- -------------------------------------------------------------------------- ------------- ----------
  **Ribosome-related proteins (8)**                                                                                                                    
  SRPRB                                                       Signal recognition particle receptor subunit beta                          4.68          9.97E-06
  RPL15                                                       60S ribosomal protein L15                                                  4.60          1.28E-05
  RPL13                                                       60S ribosomal protein L19                                                  4.48          1.98E-05
  RPL13                                                       60S ribosomal protein L13                                                  4.48          1.98E-05
  RPL14                                                       60S ribosomal protein L14                                                  4.45          2.15E-05
  RPS5                                                        40S ribosomal protein S5                                                   4.41          2.45E-05
  RPL4                                                        60S ribosomal protein L4                                                   3.05          1.79E-03
  NPM1                                                        NPM1 protein                                                               2.42          9.50E-03
  **Translation initiation factors (3)**                                                                                                               
  EIF2S1                                                      Eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa         3.98          1.04E-04
  EIF3D                                                       Eukaryotic translation initiation factor 3 subunit D                       2.85          3.13E-03
  EIF5B                                                       Eukaryotic translation initiation factor 5B                                2.58          6.29E-03
  **Elongation factors (4)**                                                                                                                           
  EEF1B2                                                      Elongation factor 1-beta                                                   4.08          7.56E-05
  EEF1G                                                       Elongation factor 1-gamma                                                  3.71          2.44E-04
  TUFM                                                        Elongation factor Tu, mitochondrial                                        3.38          6.74E-04
  EEF1D                                                       Elongation factor 1-delta                                                  2.50          7.67E-03
  **Enzymes for tRNA synthesis (4)**                                                                                                                   
  C22orf28                                                    tRNA-splicing ligase RtcB homolog                                          4.59          1.37E-05
  EPRS                                                        Bifunctional aminoacyl-tRNA synthetase (Glutamyl-Prolyl-tRNA Synthetase)   4.06          8.10E-05
  DARS                                                        Aspartate\--tRNA ligase, cytoplasmic                                       3.43          5.87E-04
  WARS                                                        Tryptophan\--tRNA ligase, cytoplasmic                                      2.48          8.17E-03
  **Protein folding chaperones (heat shock proteins) (11)**                                                                                            
  HSP90AB1                                                    Heat shock protein HSP 90-beta                                             4.94          4.03E-06
  PPIA                                                        Peptidyl-prolyl cis-trans isomerase A                                      4.29          3.74E-05
  CANX                                                        Calnexin                                                                   3.99          9.88E-05
  PDIA6                                                       Protein disulfide-isomerase A6                                             3.62          3.22E-04
  HSPD1                                                       60 kDa heat shock protein, mitochondrial                                   3.42          5.93E-04
  PPIB                                                        Peptidyl-prolyl cis-trans isomerase B                                      3.28          9.25E-04
  HSPH1                                                       Heat shock protein 105 kDa                                                 3.18          1.22E-03
  HSPA8                                                       Heat shock cognate 71 kDa protein                                          3.11          1.49E-03
  PDIA3                                                       Protein disulfide-isomerase A3                                             2.53          7.22E-03
  HSP90B1                                                     Endoplasmin                                                                2.43          9.33E-03
  PDIA4                                                       Protein disulfide-isomerase A4                                             2.13          1.89E-02

**-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and corresponding p-values derived from the analysis of these clinical samples.**

MCF7-WNT1/FGF3 cells show a functional increase in mitochondrial mass and mitochondrial membrane potential {#s2_5}
----------------------------------------------------------------------------------------------------------

To further validate the mitochondrial phenotype of MCF7-WNT1/FGF3 cells, we used fluorescent probes to quantitate mitochondrial mass and mitochondrial membrane potential by FACS analysis. For this purpose, we used MitoTracker Deep-Red (640-nm) to measure mitochondrial mass and MitoTracker Orange (561-nm), as a measure of mitochondrial membrane potential.

Figure [5](#F5){ref-type="fig"} (Left panels) show that as compared to EV control MCF7 cells, MCF7 cells overexpressing WNT1/FGF3 show a clear shift to the right, for both mitochondrial mass and membrane potential. Furthermore, quantitation of fluorescence intensity (MFI) reveals that both of these mitochondrial parameters are significantly elevated in MCF7-WNT1/FGF3 cells (Figure [5](#F5){ref-type="fig"} (Right panels)).

![WNT1/FGF3 over-expressing MCF7 cells have increased mitochondrial mass and activity\
We used two different fluorescent probes to quantitate mitochondrial mass and mitochondrial membrane potential by FACS analysis. Briefly, we employed MitoTracker Deep-Red (640-nm) to measure mitochondrial mass and MitoTracker Orange (561-nm), as a measure of mitochondrial membrane potential. Note that as compared to EV control MCF7 cells, MCF7 cells overexpressing WNT1/FGF3 show a clear shift to the right, for both mitochondrial mass (Lower panels) and membrane potential (Upper panels). Quantitation of fluorescence intensity (MFI) reveals that both of these mitochondrial parameters are significantly elevated in MCF7-WNT1/FGF3 cells. P-values are as shown. These results suggest that both mitochondrial mass and function may be critical features of the CSC phenotype.](oncotarget-06-30453-g005){#F5}

These results suggest that increased mitochondrial mass and function may be important features of the anabolic CSC phenotype.

High mitochondrial mass is a key determinant of mammosphere-forming activity in parental MCF7 cells {#s2_6}
---------------------------------------------------------------------------------------------------

Based on our above observations with WNT1/FGF3 signaling, we would predict that mitochondrial biogenesis is critical for mammosphere forming activity. To test this hypothesis more directly, we metabolically fractionated untransfected parental MCF7 cells, using MitoTracker Deep-Red, as a measure of mitochondrial mass. In this context, we chose to analyze three distinct metabolic phenotypic sub-groups: i) negative cells (little or no positive staining; mito-negative group); ii) bottom 5% (mito-low group); and top 5% (mito-high group). Only live cells in each group were selected for this analysis.

Five thousand live cells from each group were then seeded per well, in 6-well low attachment plates, to measure mammosphere-forming efficiency. Remarkably, Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"} directly show that increasing mitochondrial mass results in a 3.0 to 5.5-fold increase in mammosphere-forming activity, depending on which gating parameters are used (singlet-gating vs. all live cells). A comparison with all live cells is also shown because mammary stem cells tend to be larger than non-stem cells (See Ref \# 37 for a discussion of this point).

![Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity: Gating for singlet cells\
We metabolically fractionated parental MCF7 cells, using MitoTracker Deep-Red, as a measure of mitochondrial mass. In this context, we chose to analyze three distinct metabolic phenotypic groups: i) negative cells (little or no positive staining; mito-negative group); ii) bottom 5% (mito-low group); and top 5% (mito-high group). Only live cells in each group were selected for this analysis. Five thousand live cells from each group were then seeded per well, in 6-well low attachment plates, to measure mammosphere-forming efficiency. Note that increasing mitochondrial mass results in a 3.0-fold increase in mammosphere-forming activity. Thus, the mito-deficient group showed the least sphere-forming activity, while the mito-high group showed the highest sphere-forming efficiency. Assays were performed in triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed is shown.](oncotarget-06-30453-g006){#F6}

![Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity: Gating for all live cells\
As in Figure [6](#F6){ref-type="fig"}, except that FACS gating included all live cells, not only live singlets. Under these conditions, note that increasing mitochondrial mass results in a \>5.5-fold increase in mammosphere-forming activity. Assays were performed in triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed is shown.](oncotarget-06-30453-g007){#F7}

As such, the mito-negative group showed the least 3-D sphere-forming activity, while the mito-high group showed the highest 3-D sphere-forming efficiency. Thus, we conclude that mitochondrial mass can be used to enrich for stem-like cancer cells that are able to undergo anchorage-independent propagation, under low-attachment conditions.

DISCUSSION {#s3}
==========

The mouse mammary tumor virus (MMTV) initiates mammary tumorigenesis in mice by promoter insertion adjacent to two main integration sites, namely Int-1 (Wnt1) and Int-2 (Fgf3), driving the propagation of mammary cancer stem cells \[[@R11]-[@R13], [@R20]\]. Here, we developed an isogenic cell model of MMTV signaling to facilitate protein biomarker discovery in breast cancer (Figure [8](#F8){ref-type="fig"}). More specifically, we over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. Importantly, MCF7 cells over-expressing both WNT1 and FGF3 showed a 3.5-fold increase in mammosphere formation. Proteomic analysis of this model system revealed the induction of EMT markers, mitochondrial proteins, glycolytic enzymes and protein synthesis machinery, consistent with an anabolic phenotype. The WNT1/FGF3-induced increases in mitochondrial function were validated by MitoTracker staining. Proteins up-regulated by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in breast cancer cells *in vivo*, based on the bioinformatic analysis of public datasets of laser-captured epithelial tumor cells from breast cancer patients. We believe that this isogenic cell model will accelerate the identification of new protein biomarkers to predict clinical outcomes in breast cancer patients. Remarkably, metabolic fractionation of parental MCF7 cells, via MitoTracker staining, indicated that mitochondrial mass is a key determinant of mammosphere-forming activity. The mito-negative group showed the least sphere-forming activity, while the mito-high group showed the highest sphere-forming efficiency. Thus, new mitochondrial biogenesis is critical for the successful propagation of stem-like cancer cells.

![Anabolic CSC signaling: Exploiting a humanized model of MMTV signaling to identify the characteristics of anabolic CSCs and achieve the goals of personalized medicine\
A humanized isogenic model of MMTV-signaling was generated by co-expressing WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. This model was first validated using the mammosphere assay to measure stem cell activity and then subjected to unbiased label-free proteomics analysis. WNT1/FGF3 protein targets identified in this manner were found to be transcriptionally over-expressed in human breast cancer cells *in vivo*, providing clinical validation of the success of our approach. Thus, we established that the anabolic CSC phenotype is characterized by the induction of EMT markers, mitochondrial proteins, glycolytic enzymes and protein synthesis machinery. These represent new classes of identified protein targets for drug discovery and the identification of companion diagnostics, to eradicate anabolic CSCs.](oncotarget-06-30453-g008){#F8}

Role of new mitochondrial biogenesis in WNT-signaling and asymmetric cell division in stem cells {#s3_1}
------------------------------------------------------------------------------------------------

Interestingly, two previous studies have also linked WNT signaling to new mitochondrial biogenesis, in the context of skeletal muscle function and osteoblastic differentiation \[[@R24], [@R25]\]. For example, Yoon et al performed an si-RNA screen to identify novel protein targets that are critical for driving mitochondrial biogenesis in skeletal muscle cells \[[@R24]\]. For this purpose, they screened the effects of si-RNAs on C2C12 cells, representing \>6,300 genes, using a high-throughput FACS-based assay to measure mitochondrial function. Overall, they identified \>150 proteins not previously recognized to be involved in the regulation of mitochondrial biogenesis. Bioinformatics analysis of this data set identified WNT/β-catenin signaling as a key regulator of mitochondrial biogenesis. This was functionally validated by using si-RNAs targeting β-catenin and Axin2. Moreover, treatment of C2C12 cells with Wnt3a increased mitochondrial biogenesis by nearly 2-fold, which also directly correlated with a functional increase in oxygen consumption. Expression of a dominant-negative form of TCF4 blocked the effects of Wnt3a on mitochondrial biogenesis, indicating that the canonical Wnt-pathway was responsible for the metabolic effects of Wnt3a. Interestingly, Wnt3a mediated mitochondrial biogenesis also appeared to be dependent on down-stream effectors, such as IRS-1 and c-MYC \[[@R24]\]. Therefore, the effects of WNT/β-catenin signaling on mitochondrial biogenesis, may ultimately be mediated by the c-MYC proto-oncogene.

Asymmetric cell division is required for the maintenance of the stem cell phenotype and also occurs in stem-like cancer cells. Recently, Weinberg and Sabatini assessed how mitochondria are apportioned during asymmetric cell division, using an immortalized model of mammary epithelial stem cells \[[@R26]\]. Interestingly, they observed that "newly-synthesized" mitochondria were concentrated in stem cells during asymmetric cell division, while "old" mitochondria were segregated into daughter cells. As such, asymmetric cell division requires new mitochondrial biogenesis, for the propagation the stem cell phenotype. These findings could mechanistically explain our current results, that high-mitochondrial mass (Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}) directly correlates with "stemness" and mammosphere-forming efficiency.

Role of mitochondrial biogenesis in anchorage-independent growth, in transformed fibroblasts and CSCs {#s3_2}
-----------------------------------------------------------------------------------------------------

In 1984, Klebe and Harriss described the use of a colorimetric tetrazolium dye, namely MTT, to distinguish between normal and transformed fibroblasts, when the two different immortal isogenic cell lines were co-cultured \[[@R27]\]. More specifically, they showed that SV40-transformed BALB/3T3 fibroblasts, which were undergoing anchorage-independent growth (foci-formation), were highly MTT-positive \[[@R27]\]. In contrast, non-transformed quiescent BALB/3T3 cells were MTT-negative, showing little or no staining \[[@R27]\]. As MTT-staining has largely been attributed to mitochondrial oxidative function and redox activity, these results may be the first description of an association between anchorage-independent growth and mitochondrial function.

In accordance with these findings, Fisher et al., 2011 \[[@R28]\] demonstrated that PGC1-α mediated activation of mitochondrial biogenesis is indeed required for the anchorage-independent growth of RAS-transformed fibroblasts. Moreover, recent studies with XCT790, a chemical inhibitor of the ERR-α/PGC1-α signaling network, directly showed that blocking mitochondrial biogenesis is sufficient to effectively prevent the anchorage-independent survival and propagation of epithelial CSCs \[[@R29]\]. Quantitatively similar results were also obtained with azithromycin and doxycycline \[[@R29], [@R31]\], two well-established antibiotic inhibitors of mitochondrial biogenesis, which target mitochondrial protein translation.

Thus, our current results are also consistent with the idea that mitochondrial power somehow helps to energize anchorage-independent growth, which is a key characteristic of CSCs.

Viral oncogenesis, promoter insertion and energy metabolism {#s3_3}
-----------------------------------------------------------

MMTV is known to cause the development of mammary tumors by promoter insertion proximal to cellular proto-oncogenes, that when over-expressed, confer an oncogenic phenotype. This appears to be largely through the constitutive activation of WNT/β-catenin signaling. Here, we show that this signal transduction process also leads to the activation of mitochondrial biogenesis and an increase in the machinery necessary for protein synthesis, which is characteristic of an anabolic CSC phenotype. Previous studies have also shown that the ability of WNT/β-catenin signaling to increase mitochondrial biogenesis is dependent on c-MYC activation, but in the context of skeletal muscle cells \[[@R24]\]. In further support of these ideas, MMTV Int-6 is eukaryotic translation initiation factor 3 (eIF3), which serves as a scaffolding protein to increase protein synthesis (Table [1](#T1){ref-type="table"}).

Avian leukosis virus (ALV) is another pathogen that induces cancer, via a promoter insertion-based mechanism \[[@R32], [@R33]\]. More specifically, ALV infection leads to proviral intergration and promoter insertion, driving the development of myeloid leukosis and, ultimately, frank leukemia in chickens. Interestingly, the most common ALV integration sites include c-MYC and hTERT, as well as other gene products related to mitochondrial biogenesis and function (NDUFS6 and PARK2) \[[@R34]\].

Taken together, these data imply that MMTV and ALV may induce oncogenesis by a convergent metabolic mechanism, which relies on the down-stream activation of c-MYC, driving increased mitochondrial biogenesis. Interestingly, c-MYC is also known to increase protein synthesis, by targeting translation initiation, as well as by directly increasing ribosomal biogenesis \[[@R35], [@R36]\]. As such, MMTV and ALV may both ultimately induce the anabolic CSC phenotype, via increased mitochondrial biogenesis and increased protein synthesis (Figure [9](#F9){ref-type="fig"}). In further support of this idea, hTERT over-expression also appears to be directly associated with an anabolic CSC phenotype, driving increased mitochondrial biogenesis and augmented protein synthesis \[[@R37]\]. Thus, this intriguing hypothesis, regarding the existence of a convergent metabolic mechanism, underlying MMTV and ALV oncogenesis, undoubtedly deserves further study.

![Convergent role of energy metabolism in the pathogenesis of viral oncogenesis, driven by promoter insertion: A new metabolic hypothesis\
We propose that MMTV and ALV may induce oncogenesis by a convergent metabolic mechanism, which relies on an anabolic CSC phenotype, characterized by increased mitochondrial biogenesis and augmented protein synthesis. See the Discussion section for further details. ALV, avian leukosis virus; MMTV, mouse mammary tumor virus.](oncotarget-06-30453-g009){#F9}

Mitochondrial DNA content and mitochondrial mass both increase during the transition from normal tissue to hyperplasia and malignancy {#s3_4}
-------------------------------------------------------------------------------------------------------------------------------------

Interestingly, previous studies in human endometrial cancer have monitored i) mt-DNA content (by RT-PCR) and ii) mitochondrial mass (using the enzyme activity of citrate synthase), during the transition to malignancy. More specifically, they observed that both of these parameters increased by up to 2 to 3 fold, when normal endometrial tissue was directly compared to endometrial cancer \[[@R38]\]. Similarly, they also observed that the protein expression levels of three mitochondrial-related transcription factors (TFAM, NRF1 and PGC1-alpha) were all significantly increased by nearly 2-fold \[[@R39]\]. Taken together, these results are all consistent with an increase in mitochondrial biogenesis, during the pathogenesis of tumor initiation.

Similarly, we have previously shown that markers of mitochondrial mass and mitochondrial activity are specifically localized to the basal stem cell layer in normal human mucosa, which co-localizes with Ki67, an established marker of cell proliferation \[[@R40]\]. In addition, this mitochondria-rich population of cells is dramatically expanded in head and neck cancers \[[@R40]\] and breast cancers \[[@R41]-[@R43]\]. Moreover, recombinant over-expression of mitochondrial-related proteins, such as PGC1-alpha/beta, POLRMT, MitoNEET or GOLPH3, is sufficient to promote tumor growth, by up to 3-fold, in xenografted pre-clinical models of human breast cancers \[[@R44], [@R45]\]. Finally, mitochondrial biogenesis and mass are also significantly increased in hematological malignancies, such as in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) \[[@R46]-[@R49]\].

This increase in mitochondrial mass also appears to be part of a normal developmental process, as mitochondrial biogenesis increases between 25 to 50 fold, during mammalian embryogenesis, especially from the two-cell stage to the early blastocyst \[[@R50]\]. This early stage of embryogenesis reflects the proliferative expansion normal progenitor cells. Interestingly, pluripotent ES cell lines are derived from the inner cell mass of the blastocyst.

CONCLUSIONS {#s4}
===========

In summary, the use of mitochondrial mass as a surrogate metabolic biomarker of mitochondrial biogenesis allows for the identification of stem-like cancer cells, facilitating CSC enrichment for future biomarker studies and aiding in the design of novel therapeutic interventions. In this context, MCF7 cells over-expressing WNT1/FGF3 will provide a novel model system for these ongoing investigations.

MATERIALS AND METHODS {#s5}
=====================

Materials {#s5_1}
---------

Breast cancer cell lines (MCF7 and T47D) were originally purchased from the ATCC. Gibco-brand cell culture media (DMEM and DMEM/F12) was purchased from Life Technologies. Lentiviral vectors encoding WNT1 \[EX-B0110-Lv105(puro)\] and FGF3 \[EX-A0154-Lv151(neo)\] were obtained commercially from Genecopoeia (USA), along with appropriate empty vector controls \[EX-Neg-Lv105(puro) and EX-Neg-Lv151(neo)\]. Antibodies directed against FGF3 (\# HPA012692, Sigma) and WNT1 (\# ab15251, Abcam) were also obtained commercially. MitoTracker probes (Deep-Red and Orange) were purchased from Molecular Probes, via Life Technologies.

MCF7 cell viral transduction and antibiotic selection {#s5_2}
-----------------------------------------------------

Lentiviral particles harboring human WNT1 \[EX-B0110-Lv105(puro)\] or human FGF3 \[EX-A0154-Lv151(neo)\] were prepared and used to stably transduce MCF7 cells, according to the manufacturer\'s protocol. After 24 hours, media containing the virus was removed and replaced with standard media. Cells were then selected with puromycin (2 μg/ml) or G418 (2 mg/ml), for up to 10 days. MCF7 cells harboring the empty vector alone controls were generated at the same time in parallel. MCF7-WNT1/FGF3 cells were generated by serial transduction with both WNT1 and FGF3 lentiviral vectors.

WNT1 and FGF3 immunoblotting {#s5_3}
----------------------------

Transduced MCF7 cells were seeded in 10 cm dishes for 72 hrs. Then, cells were lysed in RIPA buffer (Sigma), containing proteinase inhibitors (Roche) and kept at 4°C for 30 minutes. Lysates were collected by centrifugation for 10 minutes at 10,000 × g, and protein concentration were determined using the BCA protein assay kit (Pierce). Samples were diluted into SDS-PAGE sample buffer and were boiled for 5 minutes before being separated by SDS-PAGE, using a 4-15% gradient Mini-PROTEAN TGX Gel (Biorad). Samples were then transferred onto a nitrocellulose membrane (Biorad), blocked in 5% milk in TBS-Tween 20 (Sigma) and probed with antibodies directed against WNT1 or FGF3 and β-actin (Santa Cruz Biotechnology, \#sc-1616), using a secondary antibody at a dilution of 1 to 5000. Bound antibodies were detected using the Supersignal West Pico Chemiluminiscent substrate (ThermoScientific). Alternatively, in the laboratory, blots were also routinely processed with a blocking solution containing BSA, as a blocking agent. Similarly, other comparable antibodies directed against β-actin were used, but were obtained from different commercial sources, such as Sigma.

Assessment of mammosphere forming activity {#s5_4}
------------------------------------------

Mammosphere formation was carried out, essentially as described previously by Clarke and colleagues, without any significant modifications \[[@R51]\]. MCF7 cells were plated at a density of 500 cells/cm^2^ in mammosphere medium in culture dishes coated with poly-HEMA (Sigma, \#P3932). After 5 days, 3D spheroids with a diameter greater than 50 μm were counted using a microscope, fitted with a graticule eye-piece, and the percentage of cells which formed spheroids was calculated and normalized to one (1 = 100 % MSE; mammosphere forming efficiency). Mammosphere assays were performed in triplicate and repeated three times independently.

Conditioned media experiments {#s5_5}
-----------------------------

One million MCF7 cells transfected with WNT1/FGF3 or empty vector alone controls were plated for 24 hours in DMEM (10% FCS). Cells were then washed in PBS, the subsequently cultured for 72 hours in 10 ml of DMEM/F12 phenol-red free media (mammosphere media). Media was then collected and cells were removed by centrifugation at 1800 rpm for 10 minutes. Conditioned media was then added directly to mammosphere assays of parental untransfected breast cancer cell lines (MCF7 and T47D) in a ratio of 1:1 with fresh mammosphere formation media.

Unbiased label-free proteomics analysis {#s5_6}
---------------------------------------

Proteomics analysis was carried out essentially as we previously described, with minor modifications \[[@R52], [@R53]\]. Statistical analyses were performed using ANOVA and only fold-changes in proteins with a p-value less than 0.05 were considered significant. Unbiased proteomics and the statistical analysis of the results were performed by the Biological Mass Spectrometry Core Facility, at the Cancer Research UK Manchester Institute, under the supervision of Dr. Duncan L. Smith.

Bioinformatics analysis with publically available human breast cancer clinical data {#s5_7}
-----------------------------------------------------------------------------------

To determine the possible translational significance of our proteomics analysis, we intersected our MCF-based WNT/FGF proteomics data with human genome-wide transcriptional profiling data. These human clinical data were derived from publically available human breast cancer samples, in which breast cancer cells were separated by laser-capture microdissection from tumor stromal cells. Transcriptional profiles were analyzed from N=28 human breast cancer patients \[[@R54]\].

Analysis of mitochondrial mass and membrane potential {#s5_8}
-----------------------------------------------------

To measure mitochondrial activity, cells were stained with MitoTracker Orange (\#M7510, Invitrogen), whose accumulation in mitochondria is dependent upon membrane potential. To measure mitochondrial mass, cells were stained with MitoTracker Deep Red (\#M22426, Invitrogen), localizing to mitochondria regardless of mitochondrial membrane potential. Cells were incubated with pre-warmed MitoTracker staining solution (diluted in PBS/CM to a final concentration of 10 nM) for 30-60 min at 37°C. All subsequent steps were performed in the dark. Cells were washed in PBS, harvested, and re-suspended in 300 μL of PBS. Cells were then analyzed by flow cytometry. Data analysis was performed using FlowJo software.

Metabolic fractionation of parental MCF7 cells using MitoTracker {#s5_9}
----------------------------------------------------------------

Using MitoTracker Deep-Red staining as a marker of mitochondrial mass, we metabolically fractionated parental MCF7 cells, using FACS analysis and cell collection. In these experiments, we analyzed three different metabolic sub-groups: i) negative cells (little or no positive staining; mito-negative group); ii) bottom 5% (mito-low group); and top 5% (mito-high group). Only live cells in each group were selected for this analysis. Five thousand live cells from each group (performed in triplicate) were then seeded per well, in 6-well low attachment plates, to measure mammosphere-forming efficiency. Gating for cell size was varied to take into account the observation that stem-like mammary cells may be physically larger than "bulk" cancer cells, as was previously suggested.

This method is a further refinement of a protocol used by Farnie, Sotgia and Lisanti, in a companion study published in parallel \[[@R55]\]. Importantly, very similar results were obtained here, indicating that the method is operator independent. For example, see Figure [4](#F4){ref-type="fig"} (Panel A) in Farnie et al., 2015, for comparison purposes \[[@R55]\]; however, in this companion paper, the mito-negative group was not analyzed.

Statistical analyses {#s5_10}
--------------------

Statistical significance was determined using the Student\'s t-test or ANOVA, where appropriate. Values of less than 0.05 were considered significant. Data in figures are shown as the mean ± SEM, unless stated otherwise.
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CSCs

:   cancer stem-like cells

MMTV

:   mouse mammary tumor virus

TICs

:   tumor-initiating cells

EMT

:   epithelial-mesenchymal transition

ALV

:   avian leukosis virus

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
